Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively

Journal of Clinical Investigation

Volumn 100, Issue 9, 1997, Pages 2325-2332

  Van 't Wout, Angélique B ^a   Ran, Leonie J ^a   De Jong, Menno D ^a   Bakker, Margreet ^a   Van Leeuwen, Remko ^a   Notermans, Daan W ^a   Loeliger, A Edde ^a,c   De Wolf, Frank ^a   Danner, Sven A ^a   Reiss, Peter ^a   Boucher, Charles A B ^a,d   Lange, Joep M A ^a   Schuitemaker, Hanneke ^a,b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

AIDS; Anti retroviral therapy; Cell cycle dependency; HIV 1 biological phenotype; Ritonavir

Indexed keywords

DIDANOSINE; PROTEINASE INHIBITOR; RITONAVIR; ZIDOVUDINE;

ARTICLE; CELL CYCLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MIXTURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PHENOTYPE; PRIORITY JOURNAL; SYNCYTIUM;

EID: 1842301158     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119771     Document Type: Article

References (55)

1. Tersmette, M., R.E.Y. De Goede, B.J.M. Al, I.N. Winkel, R.A. Gruters, H.T.M. Cuypers, H.G. Huisman, and F. Miedema. 1988. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J. Virol. 62:2026-2032.
2. Cheng-Mayer, C., D. Seto, M. Tateno, and J.A. Levy. 1988. Biologic features of HIV-1 that correlate with virulence in the host. Science (Wash. DC). 240:80-82.
3. Asjo, B., J. Albert, A. Karlsson, L. Morfeldt-Månson, G. Biberfeld, K. Lidman, and E.M. Fenyö. 1986. Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet. II: 660-662.
4. Tersmette, M., R.A. Gruters, F. De Wolf, R.E.Y. De Goede, J.M.A. Lange, P.Th.A. Schellekens, J. Goudsmit, J.G. Huisman, and F. Miedema. 1989. Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J. Virol. 63:2118-2125.
5. Schuitemaker, H., M. Koot, N.A. Kootstra, M.W. Dercksen, R.E.Y. De Goede, R.P. Van Steenwijk, J.M.A. Lange, J.K.M. Eeftink Schattenkerk, F. Miedema, and M. Tersmette. 1992. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus populations. J. Virol. 66:1354-1360.
6. + T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1 infected individuals. J. Virol. 67:1772-1777.
7. Zhu, T., H. Mo, N. Wang, D.S. Nam, Y. Cao, R.A. Koup, and D.D. Ho. 1993. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science (Wash. DC). 261:1179-1181.
8. Van 't Wout, A.B., N.A. Kootstra, G.A. Mulder-Kampinga, N. Albrecht-van Lent, H.J. Scherpbier, J. Veenstra, K. Boer, R.A. Coutinho, F. Miedema, and H. Schuitemaker. 1994. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral and vertical transmission. J. Clin. Invest. 94:2060-2067.
9. Deng, H.K., R. Liu, W. Ellmeier, S. Choe, D. Unutmaz, M. Burkhart, P. Di Marzio, S. Marmon, R.E. Suttons, C.M. Hill, et al. 1996. Identification of the major co-receptor for primary isolates of HIV-1. Nature (Lond.). 381:661-666.
10. + cells is mediated by the chemokine receptor CC-CKR-5. Nature (Lond.). 381:667-673.
11. Alkhatib, G., C. Combadiere, C.C. Broder, Y. Feng, P.E. Kennedy, P.M. Murphy, and E.A. Berger. 1996. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science (Wash. DC). 272:1955-1958.
12. Choe, H., M. Farzan, Y. Sun, N. Sullivan, B. Rollins, P.D. Ponath, L. Wu, C.R. Mackay, G. LaRosa, W. Newman, et al. 1996. The β-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell. 85:1135-1148.
13. Doranz, B.J., J. Rucker, Y. Yi, R.J. Smyth, M. Samson, S.C. Peiper, M. Parmentier, R.G. Collman, and R.W. Doms. 1996. A dual-tropic primary HIV-1 isolate that uses fusin and the β-chemokine receptors CKR-5, CKR-3 and CKR-2b as fusion cofactors. Cell. 85:1149-1158.
14. Feng, Y., C.C. Broder, P.E. Kennedy, and E.A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science (Wash. DC). 272:872-877.
15. Zhang, L., Y. Huang, T. He, Y. Cao, and D.D. Ho. 1996. HIV-1 subtype and second-receptor use. Nature (Lond.). 383:768.
16. Simmons, G., D. Wilkinson, J.D. Reeves, M.T. Dittmar, S. Beddows, J. Weber, G. Carnegie, U. Desselberger, P.W. Gray, R.A. Weiss, and P.R. Clapham. 1996. Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either LESTR or CCR5 as coreceptors for virus entry. J. Virol. 70:8355-8360.
17. Oberlin, E., A. Amara, F. Bachelerie, C. Bessia, J.-L. Virelizier, F. Arenzana-Seisdedos, O. Schwartz, J.-M. Heard, I. Clark-Lewis, D.F. Legler, M. Loetscher, M. Baggiolini, and B. Moser. 1996. The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line adapted HIV-1. Nature (Lond.). 382:833-835.
18. Bleul, C.C., M. Farzan, H. Choe, C. Parolin, I. Clark-Lewis, J. Sodroski, and T.A. Springer. 1996. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature (Lond.). 382:829-832.
19. + T cell decline in vivo. Virology. 219:87-95.
20. Koot, M., A.H.V. Vos, R.P.M. Keet, R.E.Y. De Goede, W. Dercksen, F.G. Terpstra, R.A. Coutinho, F. Miedema, and M. Tersmette. 1992. HIV-1 biological phenotype in long term infected individuals, evaluated with an MT-2 cocultivation assay. AIDS. (Lond.). 6:49-54.
21. + cell depletion and progression to AIDS. Ann. Intern. Med. 118:681-688.
22. Richman, D.D., and S.A. Bozzette. 1994. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J. Infect. Dis. 169:968-974.
23. Karlsson, A., K. Parsmyr, E. Sandstrom, E.M. Fenyö, and J. Albert. 1994. MT-2 cell tropism as prognostic marker for disease progression in Human Immunodeficiency Virus type 1 infection. J. Clin. Microbiol. 32:364-370.
24. Boucher, C.A.B., J.M.A. Lange, F. Miedema, G.J. Weverling, M. Koot, J.W. Mulder, J. Goudsmit, P. Kellam, B.A. Larder, and M. Tersmette. 1992. HIV-1 biological phenotype and development of zidovudine resistance in relation to disease progression in asymptomatic individuals during treatment. AIDS (Lond.). 6:1259-1264.
25. St. Clair, M.H., P.M. Hartigan, J.C. Andrews, C.L. Vavro, M.S. Simberkoff, J.D. Hamilton, and VA Cooperative Study Group. 1993. Zidovudine resistance, syncytium-inducing phenotype, and HIV disease in a case-control study. J. Acquired Immune Defic. Syndr. 6:891-897.
26. Koot, M., P.Th.A. Schellekens, J.W. Mulder, J.M.A. Lange, M.Th.L. Roos, R.A. Coutinho, M. Tersmette, and F. Miedema. 1993. Viral phenotype and T-cell reactivity in human immunodeficiency virus type 1-infected asymptomatic men treated with zidovudine. J. Infect. Dis. 168:733-736.
27. Karlsson, A., K. Parsmyr, K. Aperia, E. Sandstrom, E.M. Fenyö, and J. Albert. 1994. MT-2 cell tropism of human immunodeficiency virus type 1 isolates as a marker for response to treatment and development of drug resistance. J. Infect. Dis. 170:1367-1375.
28. Katzenstein, D.A., S.M. Hammer, M.D. Hughes, H. Gundacker, J.B. Jackson, S. Fiscus, S. Rasheed, T. Elbeik, R. Reichman, A.J. Japour, T.C. Merigan, M.S. Hirsch, and AIDS Clinical Trials Group 175 Virology Study Team. 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N. Engl. J. Med. 335:1091-1098.
29. Van 't Wout, A.B., M.D. De Jong, N.A. Kootstra, J. Veenstra, J.M.A. Lange, C.A.B. Boucher, and H. Schuitemaker. 1996. Changes in cellular virus load and zidovudine resistance of syncytium-inducing and non-syncytium-inducing human immunodeficiency virus populations under zidovudine pressure: a clonal analysis. J. Infect. Dis. 174:845-849.
30. Delforge, M.-L., C. Liesnard, L. Debaisieux, M. Tchetcheroff, C.-M. Farber, and J.-P. Van Vooren. 1995. In vivo inhibition of syncytium inducing variants of HIV in patients treated with didanosine. AIDS (Lond.). 9:89-101.
31. Zheng, N.N., P.W. McQueen, L. Hurren, L.A. Evans, M.G. Law, S. Forde, S. Barker, and D. A. Cooper. 1996. Changes in biologic phenotype of human immunodeficiency virus during treatment of patients with didanosine. J. Infect. Dis. 173:1092-1096.
32. Burger, D.M., C.L. Kraayeveld, P.L. Meenhorst, J.W. Mulder, R.M.W. Hoetelmans, C.H.W. Koks, and J.H. Beijnen. 1995. Study on didanosine concentrations in cerebrospinal fluid. Pharm. World Sci. 17:218-221.
33. Portegies, P., J. de Gans, J.M.A. Lange, M.M.A. Derix, H. Speelman, M. Bakker, S.A. Danner, and J. Goudsmit. 1989. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment. Br. Med. J. 299: 819-821.
34. Portegies, P., R.H. Entingh, M.D. De Jong, S.A. Danner, P. Reiss, J. Goudsmit, and J.M.A. Lange. 1994. AIDS dementia complex and didanosine. Lancet (N. Am. Ed.). 344:759.
35. Schooley, R.T., C. Ramirez-Ronda, J.M.A. Lange, D.A. Cooper, J. Lavelle, L. Lefkovits, M. Moore, B.A. Larder, M.H. St. Clair, J.W. Mulder, et al. 1996. Virologic and immunologic benefits of initial therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. J. Infect. Dis. 173:1354-1366.
36. Delta Coordinating Committee. 1996. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet (N. Am. Ed.). 348:283-291.
37. Hammer, S.M., D.A. Katzenstein, M.D. Hughes, H. Gundacker, R.T. Schooley, R.H. Hauhrich, W.K. Henry, M.M. Lederman, J.P. Phair, M. Niu, M.S. Hirsch, T.C. Merigan, and for the AIDS Clinical Trials Group Study 175 Study Team. 1996. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N. Engl. J. Med. 335:1081-1090.
38. Saravolatz, L.D., D.L. Winslow, G. Collins, J.S. Hodges, C. Pettinelli, D.S. Stein, N. Markowitz, R. Reves, M.O. Loveless, L. Crane, M. Thompson, D. Abrams, and Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. 1996. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N. Engl. J. Med. 335:1099-1106.
39. Mulder, J.W., F. De Wolf, J. Goudsmit, P.A. Cload, R.A. Coutinho, A.P. Fiddian, P.Th.A. Schellekens, J. Van der Noordaa, and J.M.A. Lange. 1990. Long-term zidovudine treatment of asymptomatic HIV-1-infected subjects. Antivir. Res. 13:127-138.
40. Alpha International Coordinating Committee. 1996. The alpha trial: European/Australian randomized double-blind trial of two doses of didanosine in zidovudine-intolerant patients with symptomatic HIV disease. AIDS (Lond.). 10:867-880.
41. Danner, S.A., A. Carr, J.M. Leonard, L.M. Lehman, F. Gudiol, J. Gonzales, A. Raventos, R. Rubio, E. Bouza, V. Pintado, et al. 1995. A short-term study of the safety, pharmacokinetics, and efficacy of Ritonavir, an inhibitor of HIV-1 protease. N. Engl. J. Med. 333:1528-1533.
42. Koot, M., A.B. Van 't Wout, N.A. Kootstra, R.E.Y. De Goede, M. Tersmette, and H. Schuitemaker. 1996. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J. Infect. Dis. 173: 349-354.
43. + memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc. Natl. Acad. Sci. USA. 87:6058-6062.
44. Mulder, J., N. McKinney, C. Christopherson, J. Sninsky, L. Greenfield, and S. Kwok. 1994. A rapid and simple PCR assay for quantification of human immunodeficiency virus type-1 RNA in plasma: application to acute retroviral infection. J. Clin. Microbiol. 32:292-300.
45. van Gemen, B., R. van Beuningen, A. Nabbe, D. Van Strijp, S. Jurriaans, P. Lens, and T. Kievits. 1994. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J. Virol. Methods. 49:157-168.
46. Richman, D.D. 1995. Drug resistance in relation to pathogenesis. AIDS. 9(suppl):S49-S53.
47. Mueller, B.U., K.M. Butler, V.L. Stocker, F.M. Balis, P. Brouwers, P. Jarosinski, R.N. Husson, L.L. Lewis, D. Venzon, and P.A. Pizzo. 1994. Clinical and pharmacokinetic evaluation of long-term therapy with didanosine in children with HIV infection. Pediatrics. 94:724-731.
48. D'Aquila, R.T., V.A. Johnson, S.L. Welles, A.J. Japour, D.R. Kuritzkes, V. DeGruttola, P.S. Reichelderfer, R.W. Coombs, C.S. Crumpacker, J.O. Kahn, D.D. Richman, for the AIDS Clinical Trials Group Protocol 116B/117 Team, and the Virology Committee Resistance Working Group. 1995. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann. Intern. Med. 122:401-408.
49. St. Clair, M.H., J.L. Martin, G. Tudor-Williams, M.C. Bach, C.L. Vavro, D.M. King, P. Kellam, S.D. Kemp, and B.A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science (Wash. DC). 253:1557-1559.
50. Nielsen, C., L. Bruun, L.R. Mathiesen, C. Pedersen, and J. Gerstoft. 1996. Development of resistance to zidovudine (ZDV) and didanosine (ddI) in HIV from patients in ZDV, ddI and alternating ZDV/ddI therapy. AIDS (Lond.). 10:625-633.
51. Gao, W.Y., T. Shirasaka, D.G. Johns, S. Broder, and H. Mitsuya. 1993. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91:2326-2333.
52. Gao, W.Y., R. Agbaria, J.S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
53. Shirasaka, T., S. Chokekijchai, A. Yamada, G. Gosselin, J.-L. Imbach, and H. Mitsuya. 1995. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob. Agents Chemother. 39:2555-2559.
54. Trkola, A., T. Dragic, J. Arthos, J.M. Binley, W.C. Olson, G.P. Allaway, C. Cheng-Mayer, J. Robinson, P.J. Maddon, and J.P. Moore. 1996. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature (Lond.). 384:184-187.
55. Bleul, C.C., L. Wu, J.A. Hoxie, T.A. Springer, and C.R. Mackay. 1997. The HIV coreceptor CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc. Natl. Acad. Sci. USA. 94:1925-1930.